Eduardo Rocha

Eduardo Rocha serves as CEO at NATCOFARMA BRASIL. NATCOFARMA BRASIL operates in the pharmaceuticals sector with approximately 90.0 employees. The company is headquartered in Sao Paulo, State of Sao Paulo.

Industry & Role Insights

• • MessageCEO tracks 1,288 executives in the pharmaceuticals sector.
• • 3,750 executive contacts are available in State of Sao Paulo.
• • Our database includes 201,469 c suite-level executives.

Outlook Google Tag Manager Quantcast ShareThis YouTube BuySellAds Mobile Friendly AddThis Google Analytics Disqus Vimeo WordPress.org DoubleClick reCAPTCHA Linkedin Widget Google translate widget Google translate API Google AdSense Facebook Login (Connect) Multilingual

oncologia hematologia neurologia pharmaceutical manufacturing oncology hematology generic drugs affordable medication azacitidine bendamustine everolimus exher gefitinib letrozole sunitinib xpreza primary care apixaban oseltamivir oselflu teriflunomide vildagliptin high-quality drugs pharmaceutical research drug development active pharmaceutical ingredients fdf clinical trials patient care cancer treatment neurology cardiology research team global presence innovation healthcare access biopharmaceuticals regulatory compliance medical expertise injectable solutions oral medications drug efficacy patient education clinical guidelines medical professionals medical innovation sustainability in healthcare health technology drug affordability medical research therapeutic solutions life quality improvement pharmaceuticals medical hospital & health care health care health wellness & fitness

YM

Yathendra Madineni Chief Executive Officer at 4C Pharma Solutions

RB

Ronan Brown Chief Operating Officer at 4G Clinical

HK

Hitoshi Kamiya Chief Executive Officer at A2 Healthcare Corporation

LJ

Lars Jensen CEO at A-apoteket

TL

Tien Lee CEO at Aardvark Therapeutics, Inc.

Outreach Guidance — pharmaceuticals Sector

Executives like Eduardo Rocha in the pharmaceuticals sector receive targeted outreach from sales teams, recruiters, and investors. To stand out, personalize your message with industry-specific context and a clear, specific value proposition relevant to their role at NATCOFARMA BRASIL.

Eduardo Rocha's Position in the MessageCEO Database

• •Eduardo Rocha is 1 of 1 verified executive contact we track at NATCOFARMA BRASIL.
• •1,240 verified executive contacts in pharmaceuticals are in the MessageCEO database.
• •3,723 verified executive contacts in State of Sao Paulo are in the database.
• •4 verified contacts work at pharmaceuticals companies in the 90.0 employee range (same size as NATCOFARMA BRASIL).

Executive contact data compiled from public business filings, LinkedIn public profiles, company press materials, and verified outbound email testing. We do not publish personal addresses or sensitive identifiers. Methodology & sources · Removal requests handled at /remove-info · Updated July 2026.

How do I reach Eduardo Rocha directly?

Eduardo Rocha's verified email address is available to MessageCEO Pro subscribers. They currently serve as CEO at NATCOFARMA BRASIL. Access direct contact info to skip gatekeepers and reach the decision maker.

What company does Eduardo Rocha work for?

Eduardo Rocha is CEO at NATCOFARMA BRASIL, a company in the pharmaceuticals sector with 90.0 employees. The company is based in Sao Paulo, State of Sao Paulo.

Can I pitch or sell to Eduardo Rocha?

As CEO at NATCOFARMA BRASIL, Eduardo Rocha is a key decision-maker in the pharmaceuticals sector. MessageCEO Pro gives you verified email to reach Eduardo Rocha directly — ideal for B2B sales, partnerships, and executive recruiting.

What industry is Eduardo Rocha in?

Eduardo Rocha works in the pharmaceuticals industry as CEO at NATCOFARMA BRASIL. MessageCEO provides verified contact information for executives across all major industries.

Is Eduardo Rocha's contact information verified?

Yes. MessageCEO verifies executive contact information through multiple data sources and regular validation checks. Eduardo Rocha's profile is kept up-to-date with the latest available information.

Last updated: July 21, 2026